Myriad Genetics at Leerink Conference: Strategic Moves in Cancer Care

Myriad guided to a $870M revenue midpoint for 2026, targeting mid-single-digit sequential growth and investing $35M over multiple years to improve sales efficiency; management plans a Q3 launch of FirstGene to bolster prenatal share. CEO Sam Raha bought 40,000 shares, signaling insider confidence; hereditary cancer and GeneSight volumes are modeled to grow ~6% annually (9% exit Q4) and GeneSight added 12 payers but lost UnitedHealthcare coverage with no expectation of reinstatement, with break-even targeted in 2-3 years. ASP headwinds: portfolio ASP down ~3% in 2025 with an expected modest decline of 0%-2% in 2026; prior EMR/order-management issues are stated as resolved but will weigh on near-term prenatal recovery into Q2.

Analysis

The company’s strategic pivot toward the cancer care continuum increases optionality but concentrates execution risk: revenue upside is now front-loaded to a small set of product launches and channel changes, so near-term share moves will be driven more by operational cadence than by long-run market potential. Competitors with deeper commercial footprints and incumbent relationships can blunt share gains quickly if launches slip or if reimbursement pathways remain uncertain, making market-share wins ephemeral unless paired with durable payer wins.

Payer dynamics are the single biggest swing factor — stability in average realized price and collection turnaround will determine whether the pharmacogenomics line converts to sustained margin contribution. Policy-level shifts and state-by-state legislation create idiosyncratic tailwinds, but they are lumpy and reversible; expect binary policy/court/contract events to drive meaningful re-pricing windows over quarters, not days.

Operational improvements (product development phase gates, sales tooling, and focused channel coverage) materially reduce delivery risk only if adoption KPIs accelerate within the first two post-launch quarters; missed leading indicators (sample throughput, counseling utilization, rev-cycle days) will compress optionality fast. Conversely, a clean set of sequential quarters with improving collection metrics and stable ASPs is underappreciated by consensus and would justify re-rating versus peers that lack integrated counseling and channel reach.

Overall, the risk/return is asymmetric but execution-sensitive: upside concentrates on successful rollouts and payer traction over the next 6–18 months, while downside is capped by persistent rev-cycle and reimbursement friction that could take multiple quarters to resolve.

Key Decisions for Investors

• Long MYGN equity or 9–12 month call spread (BUY MYGN Jan+9/Jan+12 call spread) sized 1–2% PV: directional exposure to execution-led recovery into the next two product-readout windows; stop-loss at 18% drawdown and trim into any 30–40% rally to lock profits (R/R: target 2.0–3.0x if catalysts hit).
• Paired trade: Long MYGN / Short NTRA (equal notional, 9–12 month horizon): asymmetric play that monetizes relative execution and commercialization advantages if MYGN captures incremental prenatal/hereditary share while NTRA faces commoditization pressure (risk if NTRA executes faster; hedge by sizing ≤1% NAV).
• Buy downside protection on MYGN: purchase 12-month OTM put spread (e.g., 35–45% OTM) representing a 0.25–0.5% NAV insurance cost to limit tail risk from a policy reversal or operational miss; use as hedge for any meaningful long exposure.
• Monitor catalysts and quick exits: set alerts for quarterly rev-cycle metrics and two operational KPIs (genetic counseling utilization and sample throughput). If either misses two consecutive quarters, reduce long exposure by at least 50% within days.